Présentation de l'entreprise
GeneDx Holdings Corp. operates within the healthcare sector, specifically serving the diagnostics and research industry by providing specialized genetic testing services. The company's core business involves offering pediatric and rare disease diagnostics with a primary focus on whole exome and genome sequencing, alongside data and information services. It also develops an AI-based platform designed for next-generation sequencing applications to enhance diagnostic capabilities. GeneDx Holdings Corp. maintains a substantial market capitalization of $1.92B and reported annual revenue of $427.54M over the trailing twelve months, employing a workforce of 1,300 individuals. These financial figures indicate that the company holds a significant position in the genomics market, commanding a valuation that reflects investor expectations for its technological advancements in genetic diagnostics and data services.
Santé financière
The company generated revenue of $427.54M in the trailing twelve months, yet recorded a net income of $-21,021,000, while reporting an EBITDA of $12.65M. The substantial gap between the positive EBITDA and the negative net income reveals a significant cost structure burden, primarily driven by interest expenses or other non-operating costs that erode operating profitability. Despite the net loss, the company generated free cash flow of $38.06M, which indicates a degree of financial flexibility allowing for operational investments or debt servicing without relying solely on external financing. The gross margin stands at 69.7%, suggesting high pricing power or efficient production costs in its core diagnostic services, whereas the operating margin is -10.6% and the profit margin is -4.9%, indicating that overhead expenses and non-operating items are currently outweighing operating profits. The balance sheet holds $171.28M in cash against $113.17M in debt, resulting in a debt-to-equity ratio of 36.72, which suggests a leveraged capital structure where equity is relatively low compared to total debt obligations. Liquidity is robust with a current ratio of 2.46, indicating that the company holds sufficient current assets to cover its short-term liabilities nearly two and a half times over. However, the return on equity is -7.6% and the return on assets is -1.5%, revealing that management has not yet achieved positive returns on the capital invested, likely due to the company's current stage of investment in growth and R&D.
Évaluation de la valorisation
The valuation metrics present a complex picture with a trailing P/E ratio listed as N/A due to the negative net income, while the forward P/E is 31.88. The difference between a non-existent trailing P/E and a forward P/E of 31.88 implies that the market prices the stock based on anticipated future earnings recovery rather than current profitability. The price-to-book ratio is 6.22, indicating that the market values the company at more than six times its book value, which suggests a significant premium attributed to its intangible assets like intellectual property and proprietary AI platforms. Alternative valuation metrics such as a price-to-sales ratio of 4.49 and an EV/EBITDA of 147.24 further highlight that the stock is priced at a very high multiple relative to its sales and earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week low of $55.17 and a 52-week high of $170.87, meaning the current trading price sits within a wide historical range, though the specific percentage distance from the high or low fluctuates with daily market movements. The beta value of 2.19 indicates that the stock is highly volatile and is expected to move with significantly greater magnitude than the broader market, amplifying both potential gains and losses relative to market indices.
Growth & Income
GeneDx Holdings Corp. demonstrated strong top-line momentum with revenue growth of 26.5% year-over-year, while earnings growth is listed as N/A due to the current period's net loss. Since the company is not currently profitable, earnings are not growing faster than revenue in a traditional sense, but the rapid revenue expansion suggests that the path to profitability is being driven by scaling operations and market adoption. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings are theoretically reinvested into growth initiatives rather than distributed to shareholders. The overall growth and income profile characterizes the company as a high-growth, non-income stock where value creation is currently derived from expanding market share and future earnings potential rather than current cash distributions.